News
StockStory.org on MSN6h
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual ...
16h
Zacks Investment Research on MSNDenali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in FocusDenali Therapeutics DNLI reported a first-quarter 2025 loss of 78 cents per share, wider than the Zacks Consensus Estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results